Salt Lake City, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, announced today that it will present a ...
Recursion Pharmaceuticals (RXRX) is drawing renewed attention after the appointment of Najat Khan as CEO and news of a narrowing net loss, both viewed as signals of improving execution. Investors also ...
Recursion describes itself as a clinical stage TechBio company that uses its proprietary Recursion OS platform to analyze biological and chemical datasets. The company operates laboratories capable of ...
US lawmakers want disclosure of license reviews for Nvidia H200 chip sales to China Two senior Democratic lawmakers on Monday asked the U.S. Commerce Department to disclose details and any approvals ...
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...
Access detailed historical stock prices, including daily closing prices, for RXRX. Analyze past performance trends, track price movements, and explore historical data to inform your investment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback